Abstracts tagged "gout"

Abstract Number: 191 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Febuxostat in Healthy Adult Male Subjects
James VanderLugt¹, Michael Gillen², Xiaojuan Yang³ and Jesse Hall³, ¹Jasper Clinical Research & Development, Kalamazoo, MI, ²AstraZeneca, Gaithersburg, MD, ³Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: Verinurad (RDEA3170) is a novel selective uric acid reabsorption inhibitor in clinical development for the treatment of gout and asymptomatic hyperuricemia. This Phase 1,…
Abstract Number: 220 • 2016 ACR/ARHP Annual Meeting
Urate Lowering Therapy Regresses Ultrasound Abnormalities in Gout
Siddharth K. Das¹, Harikrishnan Velayudhan², Danveer Bhadu³, Urmila Dhakad⁴ and Ragini Srivastava⁵, ¹Rheumatology, Prof. and Head, Rheumatology, K.G. Medical University, Lucknow, Lucknow, India, ²Rheumatology, Senior Resident, Rheumatology, K.G. Medical University, Lucknow, India, Luknow, India, ³Rheumatology, Senior Resident III, Rheumatology, K.G. Medical University, Lucknow, India, Lucknow, India, ⁴Rheumatology, Asst Professor, K.G. Medical University, Lucknow, India, Lucknow, India, ⁵Rheumatology, Senior Research Officer, Rheumatology, K.G. Medical University, Lucknow, India, Lucknow, India
Background/Purpose: Detection of double contour sign (DCS) and hyperechoic aggregates (HAG) is a reliable method in detecting urate crystal deposition by ultrasound (US) which has…
Abstract Number: 2283 • 2016 ACR/ARHP Annual Meeting
Suppression of Monosodium Urate (MSU) Crystals-Induced Inflammatory Response By Inhibiting TGF-β Activated Kinase 1 (TAK1)
Anil Singh¹, Kayla O’Sullivan², Mukesh Chourasia³, Sadiq Umar⁴, Mahamudul Haque², Bhanupriya Madarampalli² and Salahuddin Ahmed², ¹Washington State University, College of Pharmacy, Spokane, WA, ²Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, ³Department of Pharmacoinformatics,, National lnstitute of Pharmaceutical Education and Research, Hajipur,, India, ⁴Department of Pharmaceutical Science, Washington State University, College of Pharmacy, Spokane, WA
Background/Purpose: Methods: Results: Conclusion:
Abstract Number: 192 • 2016 ACR/ARHP Annual Meeting
Pharmacodynamic and Pharmacokinetic Study of Verinurad in Adult Male Subjects with Mild, Moderate, and Severe Renal Impairment: A Phase 1, Open-Label Study
William B Smith¹, Jesse Hall², Jolene Berg³, Michal Kazimir⁴, Amy Yamamoto², Caroline Lee², Susan Walker² and Thomas C. Marbury⁵, ¹Volunteer Research Group, Knoxville, TN, ²Ardea Biosciences, Inc., San Diego, CA, ³DaVita Clinical Research, Minneapolis, MN, ⁴DaVita Clinical Research, Lakewood, CO, ⁵Orlando Clinical Research Center, Orlando, FL
Background/Purpose: Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for the treatment of gout and asymptomatic hyperuricemia. This Phase 1, single-dose, open-label study…
Abstract Number: 223 • 2016 ACR/ARHP Annual Meeting
Clinical Predictors of Acute Gout Flares within Hospitalized Patients at a Tertiary Care Center in New York
Lara El Khoury¹, Mohamad Yasmin^1,2, Nabil Zeineddine¹, Joseph Saabiye¹, Saleha Riaz¹, Sami Arnaout¹, Talal El Imad¹, Suzanne El-Sayegh³ and Rita Obeid⁴, ¹Internal Medicine, Staten Island University Hospital, Northwell Health, Staten Island, NY, ²Infectious Diseases, Case Western Reserve University, Cleveland, OH, ³Internal Medicine, Program Director, Staten Island University Hospital, Northwell Health, Staten Island, NY, ⁴Psychology, The Graduate Center, CUNY, New York, NY
Background/Purpose: Gout is the most prevalent inflammatory arthritis worldwide. Within the healthcare setting, gout flares contribute to substantial morbidity and complicated hospital stays. Identifying risk…
Abstract Number: 2284 • 2016 ACR/ARHP Annual Meeting
Differential Effect of MSU-Crystal Induced Inflammation on Macrophage Polarization
Rashid Ahmed¹, Nicole Yang², Changqi Sun³ and Anthony M. Reginato³, ¹Rhode Island Hospital, The Warren Alpert School of Medicine at Brown University, Providence, RI, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA, USA., Boston, MA, ³Division of Rheumatology, Rhode Island Hosital/The Warren Alpert School of Medicine of Brown University, Providence, RI
Background/Purpose: Gouty arthritis is a common inflammatory joint disease that arises in response to the deposition of monosodium urate (MSU) crystals in soft joints, periarticular…
Abstract Number: 193 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Pharmacodynamics, and Tolerability of Verinurad, a Selective Uric Acid Reabsorption Inhibitor, in Healthy Japanese Male Subjects
Michael Gillen¹, Jeffrey N. Miner² and Shakti Valdez³, ¹AstraZeneca, Gaithersburg, MD, ²Discovery Biology, Ardea Biosciences, Inc., San Diego, CA, ³Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: This was a Phase 1, randomized, single-blind, placebo-controlled study (. Panels of 8 Japanese male subjects were randomized in a 3:1 ratio to receive…
Abstract Number: 224 • 2016 ACR/ARHP Annual Meeting
Patient Perception of Gout Flares As a Measure of Outcome: Results from an International Study
Angelo L. Gaffo¹, Nicola Dalbeth², Kenneth G. Saag³, Jasvinder Singh³, Elizabeth J. Rahn¹, Amy S. Mudano³, Tuhina Neogi⁴, Lorenzo Cavagna⁵, Yi-Hsing Chen⁶, Ching-Tsai Lin⁷, Worawit Louthrenoo⁸, Geraldo Castelar-Pinheiro⁹, Fernando Perez-Ruiz¹⁰, Janitzia Vazquez-Mellado¹¹, Maxim Eliseev¹², Lisa K. Stamp¹³ and William Taylor¹⁴, ¹Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Auckland, Auckland, New Zealand, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Boston University School of Medicine, Boston, MA, ⁵Division of Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ⁶Taichung Veterans General Hospital, Taichung, Taiwan, ⁷Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, ⁸Div of Rheumatology, Dept of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁹Universidade do Estado do Rio de Janeiro - UERJ, Rio de Janeiro, Brazil, ¹⁰Servicio de Reumatología, Vizcaya, Spain, ¹¹Rheumatology, Hospital General de México, Mexico City, Mexico, ¹²Research Institute of Rheumatology of Russia, Moscow, Russian Federation, ¹³University of Otago, Christchurch, New Zealand, ¹⁴University of Otago, Wellington, New Zealand
Patient Perception of Gout Flares as a Measure of Outcome: Results from an International Study Background/Purpose: Attacks (flares) are one of the primary manifestations of…
Abstract Number: 2285 • 2016 ACR/ARHP Annual Meeting
12/15-Lipoxygenase Inhibition By ML351 Protects Against Uric Acid Crystal-Induced Acute Arthritis in Mice
Roxana Coras¹, Alex Stubelius², Oswald Quehenberger³ and Monica Guma¹, ¹Medicine, UCSD, La Jolla, CA, ²Skaggs School of Pharmacy and Pharmaceutical Sciences, UCSD, La Jolla, CA, ³Pharmacology, UCSD, La Jolla, CA
Background/Purpose: Treatment of acute gout involves the use of NSAIDs, colchicine or corticosteroids. Unfortunately, co-morbid conditions such as chronic kidney disease, peptic ulcer disease and…
Abstract Number: 194 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects with Gout
Jesse Hall¹, Michael Gillen², Xiaojuan Yang¹, Sha Liu¹, Susan Walker¹, Vicki Clauson¹ and Martin Kankam³, ¹Ardea Biosciences, Inc., San Diego, CA, ²AstraZeneca, Gaithersburg, MD, ³Vince and Associates Clinical Research, Inc.,, Overland Park, KS
Background/Purpose: Verinurad (RDEA3170) is a novel selective uric acid reabsorption inhibitor in clinical development for the treatment of hyperuricemia and gout. This Phase 1, single-blind,…
Abstract Number: 225 • 2016 ACR/ARHP Annual Meeting
Patterns of Joint Involvement in Gout Flares
Ana Beatriz Vargas-Santos¹, Yuqing Zhang², Na Lu¹, Nicola Dalbeth³, William J. Taylor⁴, Jaap Fransen⁵, Tim Jansen⁶, H. Ralph Schumacher Jr.⁷ and Tuhina Neogi¹, ¹Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ²Clinical Epidemiology and Training Unit, Boston University School of Medicine, Boston, MA, ³Department of Medicine, University of Auckland, Auckland, New Zealand, ⁴Department of Medicine, University of Otago, Wellington, New Zealand, ⁵Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ⁶VieCuri Medical Center, Venlo, Netherlands, ⁷Medicine, Rheumatology, U Penn & VA Med Ctr, Philadelphia, PA
Background/Purpose: Gout flares are the most common manifestations of gout. Awareness of possible disease presentations beyond the traditionally recognized podagra is essential for accurate and…
Abstract Number: 2289 • 2016 ACR/ARHP Annual Meeting
Obesity and Echocardiographic Changes in the Different Stages of Gout
Rada Gancheva¹, Atanas Kundurdjiev², Mariana Ivanova¹, Todor Kundurzhiev³ and Zlatimir Kolarov¹, ¹Medical Faculty, Medical University, University Hospital "St. Iv. Rilski", Clinic of Rheumatology, Sofia, Bulgaria, ²Medical Faculty, Medical University, University Hospital "St. Iv. Rilski", Clinic of Nephrology, Sofia, Bulgaria, ³Medical University, Faculty of Public Health, Sofia, Bulgaria
Background/Purpose: Studies on gout and its stages as a cardiovascular (CV) risk factor are few and with contradictory results. We compared echocardiographic parameters, known as…
Abstract Number: 195 • 2016 ACR/ARHP Annual Meeting
Pharmacodynamics, Pharmacokinetics, and Safety of Verinurad in Combination with Febuxostat Versus Febuxostat Alone and Verinurad Alone in Japanese Adults with Gout or Asymptomatic Hyperuricemia: A Phase 2a, Open-Label Study
Masanari Shiramoto¹, Masatoshi Sugeno², Sha Liu³, Zangong Shen³ and Jesse Hall³, ¹SOUSEIKAI PS Clinic, Fukuoka, Japan, ²AstraZeneca K.K., Osaka, Japan, ³Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: Verinurad (RDEA3170) is a high-affinity URAT1 inhibitor in development for the treatment of gout and asymptomatic hyperuricemia. This Phase 2a, randomized, open-label, single-site study…
Abstract Number: 226 • 2016 ACR/ARHP Annual Meeting
Comparing the Burden of Illness of Patients with Tophaceous and Non-Tophaceous Gout in France, Germany, Italy, Spain, UK, and USA
Puja Khanna¹, Eskinder Tafesse², Scott Baumgartner³, Anna Walker⁴ and Robert Morlock³, ¹Rheumatology, University of Michigan, Ann Arbor, MI, ²AstraZeneca Pharmaceuticals, Gaithersburg, MD, ³Ardea Biosciences, Inc., San Diego, CA, ⁴AstraZeneca Pharmaceuticals, Luton, United Kingdom
Background/Purpose: Less than 30% of gout patients achieve treatment targets and patients with tophi are less likely to achieve these goals than patients without tophi.…
Abstract Number: 2295 • 2016 ACR/ARHP Annual Meeting
A Non-Linear Relationship Between Physical Activity and Serum Uric Acid Concentrations: Nhanes 2003-2004
Nicholas Holdgate¹, Carl Pieper^2,3, Tony Ning⁴, William E. Kraus^5,6 and Kim Huffman^1,5, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, ³Biostatistics and Bioinformatics, Duke Pepper Center, Durham, NC, ⁴Triangle Orthopedic Associates, Durham, NC, ⁵Duke Pepper Center, Durham, NC, ⁶Medicine, Duke University Medical Center, Durham, NC
Background/Purpose: Hyperuricemia is a known cardio-metabolic risk factor as well as risk factor for gout. Physical activity has been found to improve many other cardio-metabolic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].